Maze Therapeutics

MAZE

Market cap $2.1B

Amy Bachrodt exercised 5,000 shares and immediately sold them for approximately $227,612 on Jan. 22, 2026. Maze Therapeutics' stock surged 157% in 2025, its first year on the stock market.

Maze Therapeutics leverages its Compass platform to translate human genetic insights into de-risked, high-probability drug candidates. MZE829 targets APOL1-mediated kidney disease with a dual inhibition strategy, potentially surpassing Vertex's first-mover approach; Phase 2 HORIZON data is expected in Q1 FY2026. MAZE's pipeline includes MZE782 for phenylketonuria and CKD, plus a promising 'skinny gene' obesity program targeting nutrient absorption.

A Maze insider recently exercised 72,500 shares and then immediately sold them for an aggregate transaction value of approximately $2.94 million. As such, the shares originated from option exercises that were fully vested and immediately liquidated.

SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that Jason Coloma, Ph.D., chief executive officer of Maze Therapeutics, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 a.m. PT.

Maze Therapeutics, Inc. ( MAZE ) Jefferies London Healthcare Conference 2025 November 20, 2025 7:00 AM EST Company Participants Jason Coloma - CEO & Director Presentation Jason Coloma CEO & Director Good morning, everyone. I'm Jason Coloma.

First-in-human data from Phase 1 trial of MZE782 support best- and first-in-class potential; two Phase 2 proof-of-concept trials in phenylketonuria (PKU) and chronic kidney disease (CKD) expected to initiate in 2026 Enrollment ongoing in Phase 2 HORIZON trial of MZE829 in broad APOL1-mediated kidney disease (AMKD); topline data for initial patients expected by the end of Q1 2026 Strong balance sheet with $383.9 million in cash, cash equivalents and marketable securities following oversubscribed private placement; cash runway into 2028 SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today reported financial results for the third quarter ended September 30, 2025, highlighting recent progress and business updates.

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced seven presentations at the American Society of Nephrology's (ASN) Kidney Week, being held November 6-9 in Houston, Texas.

SOUTH SAN FRANCISCO, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing small molecule precision medicines for patients with kidney and metabolic diseases, today announced that company management will participate in four upcoming investor conferences: Guggenheim 2nd Annual Healthcare Innovation Conference; fireside chat on Tuesday, November 11, 2025, at 9:30 a.m.

Maze Therapeutics CEO Jason Coloma on how the new biotech is taking on Kidney disease.

CNBC's Brian Sullivan sought to find the companies based in the city that were making investors the most money this year.